Diabetes expert accuses drug company of “intimidation”

The US Food and Drug Administration has upgraded the "black box" warning for rosiglitazone and related combination drugs by mentioning that 42 clinical studies indicated an increased risk of side effects such as angina and heart attack (BMJ 2007;335:586, 22 Sep doi: 10.1136/bmj.335.7620.58...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ 2007-12, Vol.335 (7630), p.1113-1113
1. Verfasser:	Burton, Bob
Format:	Artikel
Sprache:	eng
Schlagworte:	Bills Buse, John B Congressional committees Diabetes Diabetes Mellitus - drug therapy Drug Industry Drugs Executives Humans Hypoglycemic Agents - therapeutic use Interprofessional Relations Intimidation News Organizational Policy Pharmaceutical industry Physicians Thiazolidinediones - therapeutic use Yamada, Tadataka
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The US Food and Drug Administration has upgraded the "black box" warning for rosiglitazone and related combination drugs by mentioning that 42 clinical studies indicated an increased risk of side effects such as angina and heart attack (BMJ 2007;335:586, 22 Sep doi: 10.1136/bmj.335.7620.586-b ; BMJ 2007;335:1064, 24 Nov doi: 10.1136/bmj.39405.459074.4E ).
ISSN:	0959-8138 0959-8146 1468-5833 1756-1833
DOI:	10.1136/bmj.39409.458611.DB